NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Gray RN, McCrory DC, Eberlein K, et al. Self-Administered Drug Treatments for Acute Migraine Headache. Rockville (MD): Agency for Health Care Policy and Research (US); 1999 Feb. (Technical Reviews, No. 2.4.)

Cover of Self-Administered Drug Treatments for Acute Migraine Headache

Self-Administered Drug Treatments for Acute Migraine Headache.

Show details

References

  1. Adam EI. A treatment for the acute migraine attack. J Int Med Res. 1987;15(2):71–5. [PubMed: 3556262]
  2. Ad Hoc Committee on the Classification of Headache, National Institute of Neurological Diseases and Blindness. Classification of headache. JAMA. 1962;179:717–8.
  3. Akpunonu BE, Mutgi AB, Federman DJ, Volinsky FG, Brickman K, Davis RL, Gilbert C, Asgharnejad M. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med. 1995;25(4):464–9. [PubMed: 7710149]
  4. Amery WK, Waelkens J. Prevention of the last chance: an alternative pharmacologic treatment of migraine. Headache. 1983;23(1):37–8. [PubMed: 6337976]
  5. Andersson PG, Hinge HH, Johansen O, Andersen CU, Lademann A, Gotzsche PC. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. Cephalalgia. 1989;9(1):29–32. [PubMed: 2650879]
  6. Awidi AS. Efficacy of flurbiprofen in the treatment of acute migraine attacks: a double-blind cross-over study. Curr Ther Res. 1982;32(3):492–497.
  7. Banerjee M, Findley LJ. Sumatriptan in the treatment of acute migraine with aura. Cephalalgia. 1992;12(1):39–44. [PubMed: 1313746]
  8. Bates D, Ashford E, Dawson R, Ensink FB, Gilhus NE, Olesen J, Pilgrim AJ, Shevlin P. Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology. 1994;44(9):1587–92. [PubMed: 7936279]
  9. Behan PO. Isometheptene compound in the treatment of vascular headache. Practitioner. 1978;221(1326):937–9. [PubMed: 372936]
  10. Boureau F, Chazot G, Emile J, Bertin L, d’Allens H. Comparison of subcutaneous sumatriptan with usual acute treatments for migraine. French Sumatriptan Study Group. Eur Neurol. 1995;35(5):264–9. [PubMed: 8542914]
  11. Boureau F, Joubert JM, Lasserre V, Prum B, Delecoeuillerie G. Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia. 1994;14(2):156–61. [PubMed: 8062355]
  12. Bousser MG, d’Allens H, Richard A. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group. J Intern Med. 1993;234(2):211–6. [PubMed: 8393474]
  13. Bousser MG, Loria Y. Efficacy of dihydroergotamine nasal spray in the acute treatment of migraine attacks. Cephalalgia. 1985;5(Suppl 3):554–555.
  14. Brandon RA, Eadie MJ, Curran AC, Nolan PC, Presneill JJ, Patterson MC. A new formulation of aspirin: bioavailability and analgesic efficacy in migraine attacks. Cephalalgia. 1986;6(1):19–27. [PubMed: 3516407]
  15. Cady RK, Dexter J, Sargent JD, Markley H, Osterhaus JT, Webster CJ. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology. 1993;43(7):1363–8. [PubMed: 8392150]
  16. Cady RK, Rubino J, Crummett D, Littlejohn TW 3rd. Oral sumatriptan in the treatment of recurrent headache. Arch Fam Med. 1994;3(9):766–72. [PubMed: 7987510]
  17. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265(21):2831–5. [PubMed: 1851894]
  18. Carasso RL, Yehuda S. The prevention and treatment of migraine with an analgesic combination. Br J Clin Pract. 1984;38(1):25–7. [PubMed: 6367797]
  19. Chabriat H, Joire JE, Danchot J, Grippon P, Bousser MG. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia. 1994;14(4):297–300. [PubMed: 7954760]
  20. Cochrane Controlled Trials Register (CCTR) [computer program] The Cochrane Library, CD-ROM for Windows (IBM-PC) version. London: BMJ Publishing Group; 1997.
  21. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: L Erlbaum Associates; 1988.
  22. Currier RD, Westerberg MR. Evaluation of a salicylamide compound in the treatment of headache. U Mich Med Bull. 1958;24:415–8. [PubMed: 13603892]
  23. Cutler N, Claghorn J, Sramek JJ, Block G, Panebianco D, Cheng H, Olah TV, Reines SA. Pilot study of MK-462 in migraine. Cephalalgia. 1996;16(2):113–6. [PubMed: 8665577]
  24. Cutler N, Mushet GR, Davis R, Clements B, Whitcher L. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology. 1995;45(8 Suppl 7):S5–9. [PubMed: 7644082]
  25. Dahlöf C, Björkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia. 1993;13(2):117–23. [PubMed: 8495453]
  26. Dahlöf C, Edwards C, Toth A. Sumatriptan injection is superior to placebo in the acute treatment of migraine--with regard to both efficacy and general well-being. Cephalalgia. 1992;12(4):214–20. [PubMed: 1326404]
  27. Dahlöf C, Winter P, Ludlow S. Oral GR43175, a 5HT1-like agonist, for treatment of the acute migraine attack: an international study - preliminary results. Cephalalgia. 1989;9(Suppl 10):351–2.
  28. Dexter SL, Graham AN, Johnston ES, Ratcliffe DM, Wilkinson MI, Rose AJ. Double-blind controlled study of Paramax in the acute treatment of common and classical migraine. Br J Clin Pract. 1985;39(10):388–92. [PubMed: 3907680]
  29. Diamond S. Treatment of migraine with isometheptene, acetaminophen, and dichloralphenazone combination: a double-blind, crossover trial. Headache. 1976;15(4):282–7. [PubMed: 1107267]
  30. Diamond S, Freitag FG. Analgesic efficacy and safety of TNB in the acute treatment of migraine. Clin Pharmacol Ther. 1990;47(2):135.
  31. Diamond S, Freitag FG, Diamond ML, Urban G. Transnasal butorphanol in the treatment of migraine headache pain. Headache Quarterly. 1992;3(2):164–171.
  32. Diamond S, Freitag FG, Gallagher RM, Chu G, Mosnaim AD. The analgesic efficacy of transnasal butorphanol (TNB) in the acute treatment of migraine. Cephalalgia. 1989;9(Suppl 10):357.
  33. Diamond S, Medina JL. Isometheptene--a non-ergot drug in the treatment of migraine. Headache. 1975;15(3):211–3. [PubMed: 1100566]
  34. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309(6964):1286–91. [PMC free article: PMC2541778] [PubMed: 7718048]
  35. Dihydroergotamine Nasal Spray Multicenter Investigators (DNSMI) Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache. 1995;35(4):177–84. [PubMed: 7775172]
  36. DiSerio F, Patin J, Friedman A. U.S.A. trials of dihydroergotamine nasal spray in the acute treatment of migraine headache. Cephalalgia. 1989;9(Suppl 10):344–345.
  37. DiSerio F, Singer J, Friedman A. An evaluation of proquazone in the acute treatment of migraine headache. Cephalalgia. 1985;5(Suppl 3):146–7.
  38. Duke University Center for Clinical Health Policy Research. Technical Review. Rockville (MD): Agency for Health Care Policy and Research; Parenteral drug reatments for acute migraine headache. forthcoming.
  39. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci. 1993;20(2):131–7. [PubMed: 8334575]
  40. Ensink FB. Subcutaneous sumatriptan in the acute treatment of migraine. Sumatriptan International Study Group. J Neurol. 1991;238(Suppl 1):S66–9. [PubMed: 1646291]
  41. Facchinetti F, Bonellie G, Kangasniemi P, Pascual J, Shuaib A. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. Obstet Gynecol. 1995;86(6):911–6. [PubMed: 7501338]
  42. Ferrari MD, James MH, Bates D, Pilgrim A, Ashford E, Anderson BA, Nappi G. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994;14(5):330–8. [PubMed: 7828190]
  43. Findley LJ, Abbas A, Bayliss E. The acute treatment of migraine with aura with sumatriptan. Cephalalgia. 1991;11(Suppl 11):226–227.
  44. Finnish Sumatriptan Group (FSG) and the Cardiovascular Clinical Research Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol. 1991;31(5):332–8. [PubMed: 1653141]
  45. Freitag FG. The acute treatment of migraine with transnasal butorphanol (TNB) Headache Quarterly. 1993;4(Suppl 3):22–28.
  46. Friedman AP, DiSerio FJ, Hwang DS. Symptomatic relief of migraine: multicenter comparison of Cafergot® P-B, Cafergot®, and placebo. Clin Ther. 1989;11(1):170–82. [PubMed: 2497984]
  47. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol. 1996;53(12):1285–91. [PubMed: 8970458]
  48. Gawel MJ, Szalai JF, Stiglick A, Aimola N, Weiner M. Evaluation of analgesic agents in recurring headache compared with other clinical pain models. Clin Pharmacol Ther. 1990;47(4):504–8. [PubMed: 2328558]
  49. General Practitioner Research Group. Migraine treated with an antihistamine-analgesic combination. Practitioner. 1973;211(263):357–61. [PubMed: 4148490]
  50. Gerber WD, Haag G, Grotemeyer KH, Kropp P, Lindner V, Soyka D, Strenge H, Weinzierl R. Differential efficacy of ergotamine, paracetamol and ergotamine-paracetamol-combination in the treatment of acute migraine attacks: a multicenter double blind study. Cephalalgia. 1991;11( Suppl 11):174.
  51. Goadsby PJ, Zagami AS, Donnan GA, Symington G, Anthony M, Bladin PF, Lance JW. Oral sumatriptan in acute migraine. Lancet. 1991;338(8770):782–3. [PubMed: 1681162]
  52. Göbel H, Krapat S. Psychological status during migraine attack and interval before and after treatment with a selective 5-HT1-agonist. Headache. 1993;33(3):118–20. [PubMed: 8387474]
  53. Gross ML, Kay J, Turner AM, Hallett K, Cleal AL, Hassani H. Sumatriptan in acute migraine using a novel cartridge system self-injector. United Kingdom Study Group. Headache. 1994;34(10):559–63. [PubMed: 7843948]
  54. Guidotti M, Zanasi S, Garagiola U. Pirprofen in the treatment of migraine and episodic headache attacks: a placebo-controlled crossover clinical trial. J Int Med Res. 1989;17(1):48–54. [PubMed: 2651177]
  55. Hakkarainen H, Allonen H. Ergotamine vs. metroclopramide vs. their combination in acute migraine attacks. Headache. 1982;22:10–12. [PubMed: 17152739]
  56. Hakkarainen H, Gustafsson B, Stockman O. A comparative trial of ergotamine tartrate, acetyl salicylic acid and a dextropropoxyphene compound in acute migraine attacks. Headache. 1978;18(1):35–9. [PubMed: 348645]
  57. Hakkarainen H, Parantainen J, Gothoni G, Vapaatalo H. Tolfenamic acid and caffeine: a useful combination in migraine. Cephalalgia. 1982;2(4):173–7. [PubMed: 6984358]
  58. Hakkarainen H, Quiding H, Stockman O. Mild analgesics as an alternative to ergotamine in migraine. A comparative trial with acetylsalicylic acid, ergotamine tartrate, and a dextropropoxyphene compound. J Clin Pharmacol. 1980;20(10):590–5. [PubMed: 7440766]
  59. Hakkarainen H, Vapaatalo H, Gothoni G, Parantainen J. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet. 1979;2(8138):326–8. [PubMed: 89390]
  60. Havanka-Kanniainen H. Treatment of acute migraine attack: ibuprofen and placebo compared. Headache. 1989;29(8):507–9. [PubMed: 2676908]
  61. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(Suppl 7):1–96. [PubMed: 3048700]
  62. Henry P, d’Allens H. Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. Headache. 1993;33(8):432–5. [PubMed: 8262783]
  63. Hirt D, Lataste X, Taylor P. A comparison of DHE nasal spray and Cafergot® in acute migraine. Cephalalgia. 1989;9(Suppl 10):410–411.
  64. Hoffert MJ, Couch JR, Diamond S, Elkind AH, Goldstein J, Kohlerman NJ 3rd, Saper JR, Solomon S. Transnasal butorphanol in the treatment of acute migraine. Headache. 1995;35(2):65–9. [PubMed: 7737863]
  65. Holroyd KA, Cordingley GE, Pingel JD, Jerome A, Theofanous AG, Jackson DK, Leard L. Enhancing the effectiveness of abortive therapy: a controlled evaluation of self-management training. Headache. 1989;29(3):148–53. [PubMed: 2496052]
  66. Holroyd KA, Holm JE, Hursey KG, Penzien DB, Cordingley GE, Theofanous AG, Richardson SC, Tobin DL. Recurrent vascular headache: home-based behavioral treatment versus abortive pharmacological treatment. J Consult Clin Psychol. 1988;56(2):218–23. [PubMed: 3286705]
  67. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. First edition. Cephalalgia. 1991;11(1):1–12. [PubMed: 2036663]
  68. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials. 1996;17(1):1–12. [PubMed: 8721797]
  69. Jensen K, Tfelt-Hansen P, Hansen EW, Krois EH, Pedersen OS. Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice. Cephalalgia. 1995;15(5):423–9. [PubMed: 8536304]
  70. Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine. Cephalalgia. 1985;5(1):5–10. [PubMed: 3886154]
  71. Kangasniemi P, Kaaja R. Ketoprofen and ergotamine in acute migraine. J Intern Med. 1992;231(5):551–4. [PubMed: 1602293]
  72. Keele KD. The pain chart. Lancet. 1948;2:6–8. [PubMed: 18871952]
  73. Kinnunen E, Erkinjuntti T, Färkkilä M, Palomäki H, Porras J, Teirmaa H, Freudenthal Y, Andersson P. Placebo-controlled double-blind trial of pirprofen and an ergotamine tartrate compound in migraine attacks. Cephalalgia. 1988;8(3):175–9. [PubMed: 3143482]
  74. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia. 1992;12(3):169–71. [PubMed: 1623513]
  75. Krause KH, Bleicher MA. Dihydroergotamine nasal spray in the treatment of migraine attacks. Cephalalgia. 1985;5(Suppl 3):138–139.
  76. Larsen BH, Christiansen LV, Andersen B, Olesen J. Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neurol Scand. 1990;81(5):464–7. [PubMed: 2375249]
  77. Littman GS, Walker BR, Schneider BE. Reassessment of verbal and visual analog ratings in analgesic studies. Clin Pharmacol Ther. 1985;38(1):16–23. [PubMed: 3891192]
  78. Luciani RJ, Osterhaus JT, Gutterman DL. Patient preferences for migraine therapy: subcutaneous sumatriptan compared with other medications. J Fam Pract. 1995;41(2):147–52. [PubMed: 7636454]
  79. MacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia. 1993;13(2):124–7. [PubMed: 8495454]
  80. Massiou H. Dihydroergotamine nasal spray in prevention and treatment of migraine attacks: two controlled trials versus placebo. Cephalalgia. 1987;7(Suppl 6):440–441.
  81. Massiou H, Serrurier D, Lasserre O, Bousser MG. Effectiveness of oral diclofenac in the acute treatment of common migraine attacks: a double-blind study versus placebo. Cephalalgia. 1991;11(2):59–63. [PubMed: 1860132]
  82. Mathew NT, Dexter J, Couch J, Flamenbaum W, Goldstein J, Rapoport A, Sheftell F, Saper J, Silberstein S, Solomon S, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271–6. [PubMed: 1333181]
  83. Million R, Finlay BR, Whittington JR. Clinical trial of flupirtine maleate in patients with migraine. Curr Med Res Opin. 1984;9(3):204–12. [PubMed: 6389014]
  84. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Controlled Clin Trials. 1995;16(1):62–73. [PubMed: 7743790]
  85. Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol. 1991;31(5):314–22. [PubMed: 1653139]
  86. Nappi G, Micieli G, Tassorelli C, Viotti E, Altavilla T. Effectiveness of a piroxicam fast dissolving formulation sublingually administered in the symptomatic treatment of migraine without aura. Headache. 1993;33(6):296–300. [PubMed: 8349471]
  87. Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol. 1994;241(3):138–44. [PubMed: 8164015]
  88. Nestvold K. Naproxen and naproxen sodium in acute migraine attacks. Cephalalgia. 1986;6(Suppl 4):81–4. [PubMed: 3539361]
  89. Nestvold K, Kloster R, Partinen M, Sulkava R. Treatment of acute migraine attack: naproxen and placebo compared. Cephalalgia. 1985;5(2):115–9. [PubMed: 3893730]
  90. Ogden HD. Controlled studies of a new agent in vascular headache. Headache. 1963;3(1):29–31. [PubMed: 13939581]
  91. Oral Sumatriptan and Aspirin-plus-Metoclopramide Comparative Study Group (OSAM) A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol. 1992;32(3):177–84. [PubMed: 1317294]
  92. Oral Sumatriptan Dose-Defining Study Group (DDSG) Sumatriptan--an oral dose-defining study. Eur Neurol. 1991;31(5):300–5. [PubMed: 1653137]
  93. Oral Sumatriptan International Multiple-Dose Study Group (IMDSG) Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol. 1991;31(5):306–13. [PubMed: 1653138]
  94. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992;2(1):67–76. [PubMed: 10146980]
  95. Ostfeld AM. A study of migraine pharmacotherapy. Am J Med Sci. 1961;241:192–198. [PubMed: 13731505]
  96. Paiva T, Esperanca P, Marcelino L, Assis G. A double-blind trial with dihydroergotamine nasal spray in migraine crisis. Cephalalgia. 1985;5(Suppl 3):140–141.
  97. Patten JP. Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. Oral Sumatriptan Dose-Defining Study Group. J Neurol. 1991;238(Suppl 1):S62–5. [PubMed: 1646290]
  98. Pearce I, Frank GJ, Pearce JM. Ibuprofen compared with paracetamol in migraine. Practitioner. 1983;227(1377):465–7. [PubMed: 6351046]
  99. Peatfield RC, Petty RG, Rose FC. Double blind comparison of mefenamic acid and acetaminophen (paracetamol) in migraine. Cephalalgia. 1983;3(2):129–34. [PubMed: 6347393]
  100. Pini LA, Sternieri E, Fabbri L, Zerbini O, Bamfi F. High efficacy and low frequency of headache recurrence after oral sumatriptan. The Oral Sumatriptan Italian Study Group. J Int Med Res. 1995;23(2):96–105. [PubMed: 7601299]
  101. Pradalier A, Rancurel G, Dordain G, Verdure L, Rascol A, Dry J. Acute migraine attack therapy: comparison of naproxen sodium and an ergotamine tartrate compound. Cephalalgia. 1985;5(2):107–13. [PubMed: 3926322]
  102. Rapoport AM, Visser WH, Cutler NR, Alderton CJ, Paulsgrove LA, Davis RL, Ferrari MD. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology. 1995;45(8):1505–9. [PubMed: 7644049]
  103. Rederich G, Rapoport A, Cutler N, Hazelrigg R, Jamerson B. Oral sumatriptan for the long-term treatment of migraine: clinical findings. Neurology. 1995;45(8 Suppl 7):S15–20. [PubMed: 7644080]
  104. Rohr J, Dufresne JJ. Dihydroergotamine nasal spray for the treatment of migraine attacks: a comparative double-blind crossover study with placebo. Cephalalgia. 1985;5(Suppl 3):142–143.
  105. Russell MB, Holm-Thomsen OE, Rishøj Nielsen M, Cleal A, Pilgrim AJ, Olesen J. A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Cephalalgia. 1994;14(4):291–6. [PubMed: 7954759]
  106. Ryan RE. Double-blind clinical evaluation of the efficacy and safety of ergostine-caffeine, ergotamine-caffeine, and placebo in migraine headache. Headache. 1970;9(4):212–20. [PubMed: 4904954]
  107. Ryan RE. A study of Midrin in the symptomatic relief of migraine headache. Headache. 1974;14(1):33–42. [PubMed: 4599014]
  108. Salonen R, Ashford E, Dahlof C, Dawson R, Gilhus NE, Luben V, Noronha D, Warter JM. Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group. J Neurol. 1994;241(8):463–9. [PubMed: 7964913]
  109. Sargent JD, Baumel B, Peters K, Diamond S, Saper JR, Eisner LS, Solbach P. Aborting a migraine attack: naproxen sodium v ergotamine plus caffeine. Headache. 1988;28(4):263–6. [PubMed: 3139584]
  110. Sargent J, Kirchner JR, Davis R, Kirkhart B. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology. 1995;45(8 Suppl 7):S10–4. [PubMed: 7644079]
  111. Schoenen J, Bulcke J, Caekebeke J, Dehaene I, De Keyser J, Hildebrand G, Joffroy A, Laloux P, Louis P, Monseu G, et al. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. Cephalalgia. 1994;14(1):55–63. [PubMed: 8200027]
  112. Scott J, Huskisson EC. Graphic representation of pain. Pain. 1976;2(2):175–84. [PubMed: 1026900]
  113. Sheftell FD, Byer J, Couch J, Curran JR, DiSerio FJ, Goldstein J, Henson T, Markley H, Mondell B. Dihydroergotamine nasal spray in the acute treatment of migraine headache. Headache. 1989;29:314.
  114. Sheftell FD, Rapoport AM, Marriott J, Saper J, Kunkel R, Steinmetzer R, Cob C. Comparison of meclomen, ergotamine tartrate with caffeine and placebo for the treatment of acute headaches: a double-blind parallel-group multi-center study. Headache. 1988;28(4):299.
  115. Slettnes O, Sjaastad O. Metoclopramide during attacks of migraine. In: Sicuteri F, editor. Headache: new vistas. Florence: Biomedical Press; 1977. pp. 201–204.
  116. Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol. 1993;82(5):769–72. [PubMed: 8414324]
  117. Somerville BW. Treatment of migraine attacks with an analgesic combination (Mersyndol) Med J Aust. 1976;1(23):865–6. [PubMed: 787738]
  118. Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology. 1994;44(6 Suppl 4):S17–23. [PubMed: 8008222]
  119. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325(5):316–21. [PubMed: 1647495]
  120. Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol. 1991;31(5):323–31. [PubMed: 1653140]
  121. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet. 1995;346(8980):923–6. [PubMed: 7564725]
  122. Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia. 1984;4(2):107–11. [PubMed: 6375873]
  123. Thomson AN, Arthur GP, Bergin PS, Pollock M, Parkin PJ, Flanagan M, Samson SA. Subcutaneous sumatriptan in acute treatment of migraine: a multicentre New Zealand trial. NZ Med J. 1993;106(955):171–3. [PubMed: 8389026]
  124. Tokola RA, Kangasniemi P, Neuvonen PJ, Tokola O. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia. 1984;4(4):253–63. [PubMed: 6394143]
  125. Touchon J, Bertin L, Pilgrim AJ, Ashford E, Bes A. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology. 1996;47(2):361–5. [PubMed: 8757005]
  126. Treves TA, Streiffler M, Korczyn AD. Naproxen sodium versus ergotamine tartrate in the treatment of acute migraine attacks. Headache. 1992;32(6):280–2. [PubMed: 1399547]
  127. Tulunay FC, Karan O, Aydin N, Culcuoglu A, Guvener A. Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo. Cephalalgia. 1987;7(2):131–3. [PubMed: 3301001]
  128. Uzogara E, Sheehan DV, Manschreck TC, Jones KJ. A combination drug treatment for acute common migraine. Headache. 1986;26(5):231–6. [PubMed: 3522481]
  129. Visser WH, Ferrari MD, Bayliss EM, Ludlow S, Pilgrim AJ. Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. Cephalalgia. 1992;12(5):308–13. [PubMed: 1330318]
  130. Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology. 1996;46(2):522–6. [PubMed: 8614525]
  131. Waelkens J. Domperidone in the prevention of complete classical migraine. Br Med J (Clin Res Ed) 1982;284(6320):944. [PMC free article: PMC1496523] [PubMed: 6802362]
  132. Waelkens J. Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia. 1984;4(2):85–90. [PubMed: 6375874]
  133. Wallenstein SL, Heidrich G 3d, Kaiko R, Houde RW. Clinical evaluation of mild analgesics: the measurement of clinical pain. Br J Clin Pharmacol. 1980 Oct;10(Suppl 2):319S–327S. [PMC free article: PMC1430185] [PubMed: 7437271]
  134. Waters WE. Controlled clinical trial of ergotamine tartrate. Br Med J. 1970a;1(5705):325–7. [PMC free article: PMC1700155] [PubMed: 4913961]
  135. Waters WE. A randomized controlled trial of ergotamine tartrate. Br J Prev Soc Med. 1970b;24(1):65. [PMC free article: PMC1059255] [PubMed: 4908199]
  136. Winner P, Ricalde O, Leforce B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs. subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol. 1996;53(2):180–184. [PubMed: 8639069]
  137. Yuill GM, Swinburn WR, Liversedge LA. A double-blind crossover trial of isometheptene mucate compound and ergotamine in migraine. Br J Clin Pract. 1972;26(2):76–9. [PubMed: 4552744]
  138. Ziegler D, Ford R, Kriegler J, Gallagher RM, Peroutka S, Hammerstad J, Saper J, Hoffert M, Vogel B, Holtz N, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology. 1994;44(3 Pt 1):447–53. [PubMed: 8145914]

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...